Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM

Irinotecan has radiosensitizing effects and shows synergism with nitrosoureas. We performed a Phase II study of RT and irinotecan, followed by BCNU plus irinotecan in newly-diagnosed GBM. The MTD for patients receiving enzyme-inducing anticonvulsants (EIAC) was as follows: irinotecan 400 mg/m(2)/wee...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Jaeckle, Kurt A., Ballman, Karla V., Giannini, Caterina, Schomberg, Paula J., Ames, Matthew M., Reid, Joel M., McGovern, Renee M., Safgren, Stephanie L., Galanis, Evanthia, Uhm, Joon H., Brown, Paul D., Hammack, Julie E., Arusell, Robert, Nikcevich, Daniel A., Morton, Roscoe F., Wender, Donald B., Buckner, Jan C.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2897141/
https://ncbi.nlm.nih.gov/pubmed/20063115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-009-0103-2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller